首页> 外文OA文献 >Intracavitary chemotherapy with epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) is not superior to TKI monotherapy in controlling malignant pleural effusion recurrence in EGFR-mutated lung cancer patients

【2h】

Intracavitary chemotherapy with epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) is not superior to TKI monotherapy in controlling malignant pleural effusion recurrence in EGFR-mutated lung cancer patients

机译：具有表皮生长因子受体 - 酪氨酸激酶抑制剂（EGFR-TKI）的内部化学疗法不优于TKI单疗法控制EGFR-突变肺癌患者的恶性胸腔积液复发

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
引文网络
相似文献
相关主题

著录项

作者
Wenxian Wang; Xiaowen Jiang; Yiping Zhang; Yong Song; Zhengbo Song;
展开▼
作者单位

展开▼
年度 2019
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
中文文献
专利

1. Intracavitary chemotherapy with epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) is not superior to TKI monotherapy in controlling malignant pleural effusion recurrence in EGFR-mutated lung cancer patients [J] . Wenxian Wang, Xiaowen Jiang, Yiping Zhang, Journal of Thoracic Disease . 2019,第9期

机译：具有表皮生长因子受体 - 酪氨酸激酶抑制剂（EGFR-TKI）的内部化学疗法不优于TKI单疗法控制EGFR-突变肺癌患者的恶性胸腔积液复发
2. Effective assessment of low times MET amplification in pleural effusion after epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) acquired resistance: Cases report [J] . Wang Chang-guo, Zeng Da-xiong, Huang Jian-an, Medicine. . 2018,第1期

机译：有效评估表皮生长因子受体酪氨酸激酶抑制剂（EGFR-TKIs）获得性耐药后胸腔积液中低倍MET扩增的情况：病例报告
3. Efficacy of first-line treatment with epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) alone or in combination with chemotherapy for advanced non-small cell lung cancer (NSCLC) with low-abundance mutation [J] . Yan Xiangtao, Wang Huijuan, Li Peng, Lung cancer: Journal of the International Association for the Study of Lung Cancer . 2019,第期

机译：单独或与低丰度突变的先进非小细胞肺癌（NSCLC）组合单独使用表皮生长因子受体 - 酪氨酸激酶抑制剂（EGFR-TKI）的疗效。
4. QSAR Study of Quinazoline Derivatives as Inhibitor of Epidermal Growth Factor Receptor-Tyrosine Kinase (EGFR-TK) [C] . La Ode Aman, Widisusanti Abdulkadir, Julitha Geybie Rembet, International Conference on Computation for Science and Technology . 2015

机译：喹唑啉衍生物作为表皮生长因子受体 - 酪氨酸激酶（EGFR-TK）抑制剂的QSAR研究
5. Predictive Biomarkers of the Efficacy of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Treating Advanced Non-small Cell Lung Cancer: A Systematic Review of Randomized Controlled Trials [D] . Yang, Zuyao. 2014

机译：表皮生长因子受体酪氨酸激酶抑制剂治疗晚期非小细胞肺癌疗效的预测生物标志物：随机对照试验的系统评价。
6. Intracavitary chemotherapy with epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) is not superior to TKI monotherapy in controlling malignant pleural effusion recurrence in EGFR-mutated lung cancer patients [O] . Wenxian Wang, Xiaowen Jiang, Yiping Zhang, 2019

机译：在表皮生长因子受体酪氨酸激酶抑制剂（EGFR-TKI）的腔内化疗在控制EGFR突变的肺癌患者中控制恶性胸腔积液复发方面不优于TKI单药治疗
7. Effective assessment of low times MET amplification in pleural effusion after epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) acquired resistance [O] . Chang-guo Wang, Da-xiong Zeng, Jian-an Huang, 2018

机译：有效评估表皮生长因子受体 - 酪氨酸激酶抑制剂（EGFR-TKIs）获得性抗性后胸腔积液中的低次达到扩增

Intracavitary chemotherapy with epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) is not superior to TKI monotherapy in controlling malignant pleural effusion recurrence in EGFR-mutated lung cancer patients

著录项

引文网络

相似文献

相关主题

期刊订阅